The short version of obesity research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-29 and is reviewed periodically as new material appears.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Disease progression is similar to type II but sometimes with few visible skin changes. Type IV infection: This type of NF accounts for less than 1% of cases. It is mostly caused by the Candida albicans fungus. Risk factors include age and immunodeficiency.
== Immune system == Movement of cells is vital for the function of the immune system, and especially for antigen presenting cells. Dendritic cells (one of the main antigen presenting cells in the immune system), move towards the lymph nodes after phagocytizing an antigen in order to present the antigen to T cells. Chemokines influence these movements, especially CCL21, which is bound to lymphatic endothelial cell membranes. The influence is short range, but causes movement of the dendritic cells up a fixed chemical gradient. Other leukocytes also exhibit haptotactic movement: neutrophils undergo IL-8 mediated migration, while monocytes, basophils, eosinophils and some T cells are influenced by RANTES chemokines. In the autoimmune disorder rheumatoid arthritis and in osteoarthritis, the associated swelling and migration of neutrophils to the affected site has been shown to be linked to membrane bound midkine cytokine. This cytokine operates in a haptotactic fashion, attracting local neutrophils to the site of expression.
The BBC tells Gary Lineker he cannot present BBC One's Match of the Day until an agreement can be reached over his social media use. COVID-19 in the UK: Office for National Statistics data for the week ending 28 February indicates COVID-19 cases are rising in Scotland, but the picture is unclear in the rest of the UK. In England, the number of people testing positive for COVID-19 was estimated to be 1,333,400, equating to 2.38% of the population, or around 1 in 40 people. In Scotland, the figure was 128,400, equating to 2.44% of the population or around 1 in 40 people. 11 March The BBC apologises for 'limited' sports broadcasts, as a growing number of TV and radio presenters drop out of key programmes in support of Gary Lineker, amid an ongoing debate over impartiality. The Bank of England announces that the UK arm of Silicon Valley Bank is to enter insolvency, following the demise of its US parent, the largest banking collapse since the 2008 financial crisis. Many UK tech startups are prevented from accessing cash to pay staff. 12 March – The UK government announces that charges for prepayment energy meters are to be brought into line with those for customers paying by direct debit from 1 July, saving an average of £45 per year. 13 March HSBC agrees to buy the UK arm of Silicon Valley Bank, allowing UK tech firms and customers to access money and services as normal. Gary Lineker is allowed to return to presenting football, as the BBC announces an independent review of its social media guidelines.
=== Novel applications === Due to the versatility of SPR instrumentation, this technique pairs well with other approaches, leading to novel applications in various fields, such as biomedical and environmental studies. When coupled with nanotechnology, SPR biosensors can use nanoparticles as carriers for therapeutic implants. For instance, in the treatment of Alzheimer's disease, nanoparticles can be used to deliver therapeutic molecules in targeted ways. In general, SPR biosensing is demonstrating advantages over other approaches in the biomedical field due to this technique being label-free, lower in costs, applicable in point-of-care settings, and capable of producing faster results for smaller research cohorts. In the study of environmental pollutants, SPR instrumentation can be used as a replacement for former chromatography-based techniques. Current pollution research relies on chromatography to monitor increases in pollution in an ecosystem over time. When SPR instrumentation with a Kretschmann prism configuration was used in the detection of chlorophene, an emerging pollutant, it was demonstrated that SPR has similar precision and accuracy levels as chromatography techniques. Furthermore, SPR sensing surpasses chromatography techniques through its high-speed, straightforward analysis.
The number of COVID-19 hospital cases in Scotland have surpassed the previous winter's peak, data shows, with 448 people in hospital with the disease in the week ending 30 June, an increase on the previous week, and above the winter peak of 388. A team looking into how the Cass Review could apply to Scotland's health services for children and young adults recommends the Scottish Government pause the use of puberty blockers until further research into them is conducted. 7 July – Keir Starmer makes his first visit to Scotland as prime minister, for a meeting with First Minister John Swinney. 9 July – In an open letter to SNP members following the party's defeat in Scotland, former deputy leader Jim Sillars has described John Swinney's leadership as "a busted flush" and Nicola Sturgeon as "Stalin's wee sister". Brian Boyd, the Provost of Angus, resigns after berating a female councillor to the point of tears at an open council meeting. 11 July – The SNP confirms it will have to make the majority of its Westminster staff redundant after Parliament reduces its "Short Money" – the annual amount paid to opposition parties – by £1m. Data from Public Health Scotland indicates there were 49 COVID-related deaths in the week ending 1 July, with numbers having increased on previous weeks, while data obtained by BBC News indicates that as many as 260,000 people in at risk groups had not received a booster vaccine during the Spring 2024 programme when it ended on 30 June.
Sources: en.wikipedia.org
Placebo-adjusted lean body mass was increased by 4.8% at 0.5 mg/day, 7.2% at 1 mg/day, and 9.1% at 2 mg/day after 12 weeks. As of 2023, LGD-4033 has been less studied than other SARMs like enobosarm, with only three small phase 1 clinical trials and one phase 2 trial, or a total of four clinical studies, having been conducted and reported.
== Veterinary use == Leuprorelin is frequently used in ferrets for the treatment of adrenal disease. Its use has been reported in a ferret with concurrent primary hyperaldosteronism, and one with concurrent diabetes mellitus. It is also used to treat pet parrots with chronic egg laying behavior.
Human Genome Project (HGP) A collaborative international scientific research project with the goal of sequencing all of the chromosomal DNA and identifying and mapping all of the genes within human cells, and ultimately of assembling a complete reference genome for the human species. The project was launched in 1990 by a consortium of federal agencies, universities, and research institutions and was declared complete in 2003. Because each individual human being has a unique genome, the finished reference genome is a mosaic of sequences obtained by sampling DNA from thousands of individuals across the world and does not represent any one individual.
== Amino acid profile == Hemp protein is rich in essential amino acids, containing, in sufficient quantities, all essential amino acids required by humans except lysine, which appears at lower than recommended levels for infants aged up to five years old according to Food and agricultural organization (FOA) standards; still, the overall nutritive value of hemp protein remains relatively good, as sulfur-containing amino acids are higher than in casein or soy, while other non-essential amino acids present in hemp protein, such as arginine, provide additional health benefits including cardiovascular support, immune function optimization, and muscle repair. Hemp protein has unique properties that are useful in food processing. Its cysteine-rich amino acid composition and high sulfhydryl (-SH)/disulfide (S-S) ratio offer a glimpse of its distinctive features. These features can facilitate the development of new food materials.
Biotechnology is a rapidly evolving field with significant potential to address pressing global challenges and improve the quality of life for people around the world; however, despite its numerous benefits, it also poses ethical and societal challenges, such as questions around genetic modification and intellectual property rights. As a result, there is ongoing debate and regulation surrounding the use and application of biotechnology in various industries and fields.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.